Weill Cornell Medicine, New York, NY; NewYork-Presbyterian Hospital, New York, NY.
Memorial Sloan Kettering Cancer Center, New York, NY.
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e549-e554. doi: 10.1016/j.clml.2022.02.003. Epub 2022 Feb 22.
Clinical trials are often an important component of cancer care but are misunderstood by many patients. Few studies have examined age differences in clinical trial understanding in older versus younger adults, especially among patients with indolent non-Hodgkin lymphoma (NHL), a slowly progressive and not typically curable cancer diagnosed primarily in older adults.
Participants aged ≥21 years with a diagnosis of NHL were recruited from a single academic medical center in an urban setting. Age was dichotomized as <65 and ≥65 years. Clinical trial understanding was assessed using a four-item survey of potential goals of a clinical trial, with responses including "yes," "no," and "I don't know." Survey responses were examined by age using Chi-square tests.
The sample was comprised of 74 patients who were predominantly non-Latino White, with a mean age of 60.4 years (SD = 12.27). Compared to younger patients, older patients were more likely to respond "I don't know" to the clinical trial goals of reducing the lymphoma (41.4% vs. 13.3%; P = .023) and keeping the lymphoma from worsening (41.4% vs. 13.3%; P = .017). Age differences for the remaining goals were not statistically significant. Similar findings emerged when the sample was restricted to patients under active surveillance.
Relative to younger adults, older adults may have a less nuanced understanding of clinical trial goals. Therefore, older adults may benefit from developmentally-tailored interventions to improve clinical trial understanding. Future research should examine the relationship between clinical trial understanding and enrollment by age using validated measures in diverse samples.
临床试验通常是癌症治疗的重要组成部分,但许多患者对此存在误解。很少有研究调查过年龄对临床试验理解的影响,尤其是在年龄较大的非霍奇金淋巴瘤(NHL)患者中,这种癌症进展缓慢,通常无法治愈,主要在老年人中诊断。
在一个城市环境中的一家学术医学中心招募了年龄≥21 岁且患有 NHL 的参与者。年龄分为<65 岁和≥65 岁。使用一个包含四项潜在临床试验目标的调查评估临床试验理解程度,回答选项包括“是”、“否”和“不知道”。使用卡方检验按年龄分析调查回答。
样本由 74 名患者组成,他们主要是非拉丁裔白人,平均年龄为 60.4 岁(SD=12.27)。与年轻患者相比,年长患者对减少淋巴瘤(41.4%比 13.3%;P=.023)和防止淋巴瘤恶化(41.4%比 13.3%;P=.017)这两个临床试验目标回答“不知道”的可能性更高。对于其余目标,年龄差异没有统计学意义。当将样本限制在正在接受主动监测的患者中时,也出现了类似的发现。
与年轻成年人相比,年长成年人可能对临床试验目标的理解不够细致。因此,年长成年人可能受益于为提高临床试验理解而量身定制的发展干预措施。未来的研究应该使用验证过的方法在不同的样本中检查临床试验理解程度与年龄之间的关系。